Webcast: Identifying and Addressing Elevated Sodium Intake to Decrease Cardiovascular Risk

Increased sodium intake is considered to be a leading risk factor for cardiovascular disease (CVD), Additionally, the impact of commonly-used medications with high sodium content contributes to this burden.  As such, it is important to address the risk of increased sodium intake in patients with CVD or at CVD risk, including in patients with sleep disorders, as well as practical strategies to minimize the impact of elevated sodium.

In this webcast, multidisciplinary experts discuss the concepts listed below and engage in meaningful discussions about strategies to minimize the impact of total daily sodium intake on CVD risk.

  • The Impact of Increased Sodium on CVD Risk and CVD Outcomes

  • Hypertension and Beyond: Impact of Sodium Across the CVD Spectrum

  • Practical Strategies to Address the Impact of Increased Sodium Intake on CVD Risk

Target Audience

U.S. based sleep specialists, psychiatrists, neurologists, pulmonologists, primary care physicians, nurses, nurse practitioners, physician assistants, pharmacists and allied healthcare professionals.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Summarize the data about the association of increased sodium intake and its impact on CVD risk and CVD outcomes.
  • List current recommendations on daily sodium intake in adults with CVD or at-risk for CVD.
  • Consider the full spectrum of CVD risk beyond hypertension when evaluating sodium intake, including in patients with sleep disorders, cardiovascular and cardiometabolic comorbidities, and those using medications high in sodium content.
  • Develop practical strategies to minimize the impact of dietary and non-dietary sodium to reduce CVD risk.

Additional Information

AttachmentSize
PDF icon Transcription - Part 1 The Impact of Increased Sodium on CVD Risk and CVD Outcomes162.28 KB
PDF icon Transcription - Part 2 Hypertension and Beyond: Impact of Sodium Across the CVD Spectrum160.69 KB
PDF icon Transcription - Part 3 Practical Strategies to Address the Impact of Increased Sodium Intake on CVD Risk183.28 KB
Course summary
Available credit: 
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
07/06/2023
Course expires: 
07/06/2024
Rating: 
0

Virend K. Somers, MD, PhD (Chair)
Professor of Medicine, Mayo Clinic
Rochester, MN

Dr. Somers discloses the following: 
•    Advisor: Good Sleep 

 

Gregg S. Pressman MD, FACC, FASE
Director of Academics
Division of Cardiology
Einstein Medical Center Philadelphia
Professor of Medicine
Thomas Jefferson University
Philadelphia, PA

Dr. Pressman discloses the following: 

  • Consultant: Jazz Pharmaceuticals 

 

Deborah J. Clegg, PhD, RD
Vice President for Research
Professor, Internal Medicine
Texas Tech University Health Sciences Center
El Paso, TX

Dr. Clegg has nothing to disclose. 

 

 

 

ESTIMATED TIME TO COMPLETE ACTIVITY
1.0 hour

EDUCATIONAL GRANT SUPPORT

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

JOINT PROVIDERSHIP STATEMENT
A picture containing text, clipart Description automatically generated

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.

PHARMACY CONTINUING EDUCATION

PACE designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-23-163-H01-P. Type of activity: Knowledge

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no registration fees for this activity. During the period July 6, 2023 through July 6, 2024, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation.  Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.

For additional information about the accreditation of this activity, please visit https://partnersed.com

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

DISCLOSURES
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The CMHC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

DISCLOSURE OF CONFLICT OF INTEREST
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

DISCLOSURE OF UNLABELED USE 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

DISCLAIMER 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Available Credit

  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.